Apimeds Pharmaceuticals US Overview
Latest P/E ratio for Apimeds Pharmaceuticals US: -0.07 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-0.07
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for APUS is -0.07. That is below the sector sector average of 47.3. Investors often review this figure alongside Apimeds Pharmaceuticals US's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, APUS currently prints -0.07 for P/E ratio, while the sector average sits near 47.3. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at Apimeds Pharmaceuticals US's growth, margins, and balance sheet.
A P/E ratio of -0.07 for Apimeds Pharmaceuticals US is not 'good' or 'bad' on its own. Compare it with the peer average (47.3) and with APUS's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting APUS's P/E ratio (-0.07), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
